ArticleBlood research2026
Correspondence on: "Targeting the HERV-K102 envelope elicits pyroptosis and represents a novel therapeutic strategy for acute myeloid leukemia".
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zong et al. reported that CRISPR-Cas9-mediated deletion of the HERV-K102 envelope (K-Env) induces apoptosis and pyroptosis in acute myeloid leukemia cells via S100A9/NLRP3 inflammasome activation. We examine four methodological concerns: the absence of evidence using a pathway-specific inhibitor to distinguish pyroptosis from secondary necrosis; the lack of a mechanistic rescue experiment confirming S100A9 as the proximal driver; the non-specificity of primers at the mRNA level; and the inability of the immunocompromised xenograft model to capture immune evasion by K-Env. The prognostic and therapeutic implications of the study require qualification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.